Nanobiotix is a pioneering brand in the field of nanomedicine, dedicated to pushing the boundaries of therapeutic possibilities for patients worldwide. With over two decades of experience, Nanobiotix has spearheaded breakthroughs in medicine by harnessing the power of physics in developing innovative treatments. Their team is driven by the belief that finding a cure for cancer requires exploring beyond existing scientific frontiers.

They take pride in delivering cutting-edge and highly effective treatments to patients, while also creating value for stakeholders. Nanobiotix's leadership team is comprised of experts in their respective fields, including Chief Executive Officer Laurent Levy and Chief Clinical and Medical Affairs Officer Leonard A. Farber, MD.

The brand's scientific advisory board includes notable professionals in surgical, radiation, and medical oncology, who provide invaluable insights and expertise. Nanobiotix's flagship product, NBTXR3, has already been administered to over 350 patients, while involving more than 400 healthcare providers in their clinical trials. The brand's commitment to innovation and patient care has resulted in the issuance of more than 400 patents.

Join Nanobiotix in their mission to redefine the future of medicine by exploring career opportunities with their dedicated team. Contact them to learn more about their technology, collaborations, or clinical trials. Nanobiotix is at the forefront of advancing nanomedicine for the betterment of patients' lives worldwide